Robert Martinez, MD
Payments from drug & device makers
Across 117 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$242
- UCB, Inc.$188
- Otsuka America Pharmaceutical, Inc.$165
- Lundbeck LLC$158
- Teva Pharmaceuticals USA, Inc.$155
- Neurocrine Biosciences, Inc.$140
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,454100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $242 |
| UCB, Inc. | 8 | $188 |
| Otsuka America Pharmaceutical, Inc. | 8 | $165 |
| Lundbeck LLC | 5 | $158 |
| Teva Pharmaceuticals USA, Inc. | 10 | $155 |
| Neurocrine Biosciences, Inc. | 5 | $140 |
| Amneal Pharmaceuticals LLC | 5 | $103 |
| Lilly USA, LLC | 5 | $100 |
| Biohaven Pharmaceuticals, Inc. | 5 | $92 |
| Sumitomo Pharma America, Inc. | 5 | $92 |
| Catalyst Orthoscience | 1 | $89 |
| Tanabe Pharma America, Inc. | 4 | $87 |
| Pfizer | 4 | $86 |
| Upsher-smith Laboratories LLC | 3 | $69 |
| Novartis | 3 | $66 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $59 |
| Amgen | 3 | $57 |
| CSL Behring | 3 | $53 |
| Axsome Therapeutics, Inc. | 2 | $50 |
| Livanova USA, Inc. | 2 | $47 |
| Avion Pharmaceuticals | 2 | $46 |
| Tersera Therapeutics LLC | 2 | $42 |
| Biogen | 2 | $41 |
| Neurelis, Inc. | 2 | $34 |
| Harmony Biosciences LLC | 1 | $26 |
| Catalyst Pharmaceuticals, Inc. | 1 | $26 |
| Avanir Pharmaceuticals, Inc. | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| GE HealthCare | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Zyla Life Sciences, Inc. | 1 | $18 |
| AstraZeneca | 1 | $18 |
How this compares
$2,454 in reported general payments places this provider in the 50th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 55 | $670,043 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 20 | $344,130 |
| Nurtec OdtRimegepant Sulfate | 67 | $99,898 |
| Aimovig AutoinjectorErenumab-Aooe | 79 | $67,351 |
| RexultiBrexpiprazole | 30 | $49,211 |
| QuliptaAtogepant | 33 | $43,202 |
| UbrelvyUbrogepant | 17 | $21,186 |
| AptiomEslicarbazepine Acetate | 13 | $18,057 |
| Rivastigmine | 93 | $16,100 |
| Memantine Hcl | 696 | $9,958 |
| EliquisApixaban | 15 | $8,985 |
| ValtocoDiazepam | 12 | $8,231 |
| Duloxetine Hcl | 299 | $7,516 |
| Memantine Hcl ErMemantine Hcl | 58 | $7,216 |
| Levetiracetam | 258 | $6,731 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Nurtec Odt, Eliquis | $86 | $453,013102 claims |
| AbbVieQulipta, Ubrelvy | $242 | $64,38850 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $165 | $49,21130 claims |
| Neurelis, Inc.Valtoco | $34 | $8,23112 claims |
| Upsher-smith Laboratories LLCTopiramate | $69 | $1,584170 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $103 | $1,50524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,434 neurology providers in Florida.
Other neurology in Tampa
- Derrick RobertsonTampa$27.6M
- Mark CascioneTampa$12.2M
- Tuan VuTampa$7.9M
- Robert HauserTampa$7.7M
- Susan SteenTampa$7.5M
- Deborah BurkeTampa$3.1M
- Selim BenbadisTampa$3.1M
- Theresa ZesiewiczTampa$2.5M
- Peter ForsythTampa$2.3M
- Natalie MoreoTampa$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.